COMMUNIQUÉS West-GlobeNewswire

First Tracks Biotherapeutics Announces $200 Million Private Placement
15/10/2026
SAN DIEGO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in [...]
PETVIVO ANNOUNCES RELEASE OF TWO REASEARCH ABSTRACTS AND UPCOMING CONFERENCE PRESENTATIONS ON OSTEOARTHRITIS IN RHESUS MACAQUES
15/10/2026
MINNEAPOLIS, MN, Oct. 15, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV) (“PetVivo” or the “Company”), together with its subsidiaries PetVivo Animal Health, Inc., Somatrix Technologies, Inc. and PetVivo [...]
IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst Conference
15/10/2026
NEW HAVEN, Conn., Oct. 15, 2026 (GLOBE NEWSWIRE) -- IRulya Therapeutics Inc. (Nasdaq: IRLA), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapeutics for serious [...]
Daxor Accelerates Commercial Expansion of Next-Gen Blood Volume Diagnostic Platform at MedAxiom CV Transforum Fall '26
15/10/2026
FDA-cleared BVA ™ technology delivers lab-accurate precision to optimize cardiovascular service lines, reduce 30-day readmissions, and lower cost of care. Key Highlights: Commercial Acceleration: Daxor showcasing its [...]
Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy
15/10/2026
Initial Stage 1 data evaluating ven s obafusp alfa in IgAN expected by year-end 2026 Announces e xpansion cohort in patients with FSGS , with first patients anticipated to be dosed in first quarter 2027 REDWOOD CITY, [...]
Nema Health Expands Access to Specialized PTSD Treatment Through Evernorth Behavioral Health Network
15/10/2026
New in-network agreement makes evidence-based trauma treatment more accessible to eligible Cigna Healthcare and Evernorth members NEW HAVEN, Conn., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Nema Health, a virtual specialty care [...]
Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer
15/10/2026
Internally-derived candidate targets wild-type androgen receptor and clinically relevant variants implicated in resistance to conventional prostate cancer therapies MILLBRAE, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- [...]
Callio Therapeutics Wins Best New ADC Drug Developer at the 13th World ADC Awards, Presents Across Five Sessions at World ADC San Diego
15/10/2026
Callio leaders delivered three presentations and two panel discussions on dual-payload ADC resistance, manufacturability, linker design, and the path to next-generation ADCs SAN DIEGO, SEATTLE and SINGAPORE, Oct. 15, [...]
Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy
15/10/2026
LB2501 is an off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells directly within the patient after a single infusion, making it the first known dual-targeting in vivo CAR-T [...]
ORYZON further strengthens vafidemstat’s patent portfolio with new decisions to grant
15/10/2026
New patent allowances in South Korea, Mexico, New Zealand and the Philippines Further expand IP protection across BPD, ASD, aggression and social withdrawal MADRID and CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE [...]
Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis
15/10/2026
Eupraxia reached its target enrollment of 120 patients in the Phase 2b placebo-controlled blinded portion of the RESOLVE trial The Company has a statistical team who are doing periodic reviews of the unblinded data to [...]
Jyong Biotech Announces Proposed Texas Facility to Support Potential Commercialization of Its Drug Candidates
15/10/2026
New Taipei City, Taiwan, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization [...]
Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026
15/10/2026
SEATTLE, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results [...]
Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone
15/10/2026
Leading Healthcare Investors, includ ing Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital Management and other prominent healthcare specialists and mutual funds invest $200 million in [...]
DaltonTx awarded grant to accelerate AI-powered tuberculosis drug discovery
15/10/2026
Funding from the Gates Foundation supports development of open-access AI models, workflows and datasets to help researchers identify new tuberculosis (TB) targets for faster and more cost-effective drug discovery [...]
iOnctura appoints Paul Sekhri as Chair of its Board of Directors
15/10/2026
Paul Sekhri is a life science executive with more than 35 years of experience building and leading companies from early development through commercialization Appointment comes as iOnctura prepares for late-stage [...]
Mission Therapeutics doses first Parkinson’s patient in Phase 1b study of potential disease-modifying treatment MTX325
15/10/2026
MTX325 is a first-in-class, highly potent, orally bioavailable, brain-penetrant USP30 inhibitor designed to modify the course of Parkinson’s by improving mitochondrial control Phase 1b ‘MTX325-101’ study – taking place [...]
EXIT-CVD research consortium launches clinical studies to transform cardiovascular care across Europe
15/10/2026
October 15, 2026 Five-year research project unites 42 public and private partners across 17 countries to conduct 22 clinical studies involving 14,000+ patients; first patients will be enrolled this month Project aims to [...]
invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal
15/10/2026
invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal Publication in Molecular Therapy Oncology reports Phase 1 data from 17 patients with advanced, treatment- [...]

Pages